Table 3 ORR in KRAS G12C NSCLC by STK11 and KEAP1 mutation status from single arm phase II studies of sotorasib (CodeBreaK100 [94]) and adagrasib (KRYSTAL-1 [100])
From: Drugging KRAS: current perspectives and state-of-art review
| Â | Overall (%) | STK11mt, KEAP1wt (%) | STK11mt, KEAP1mt (%) | STK11wt, KEAP1mt (%) |
|---|---|---|---|---|
Sotorasib 920Â mg daily | 37.1 | 50 | 23 | 14 |
Adagrasib 600Â mg bid | 42.9 | 44.0 | 35.7 | 14.3 |